CancerDrs Find care

Testicular Cancer clinical trials in New York

10 actively recruiting testicular cancer trials at 21 sites across New York.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in New York:
  • Albany Medical Center — Albany, New York
  • Maimonides Medical Center — Brooklyn, New York
  • Roswell Park Cancer Institute — Buffalo, New York
  • Glens Falls Hospital — Glens Falls, New York
  • NYU Langone Hospital - Long Island — Mineola, New York
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in New York:
  • Albany Medical Center — Albany, New York
  • Maimonides Medical Center — Brooklyn, New York
  • Roswell Park Cancer Institute — Buffalo, New York
  • NYU Langone Hospital - Long Island — Mineola, New York
  • The Steven and Alexandra Cohen Children's Medical Center of New York — New Hyde Park, New York
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in New York:
  • New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
  • Maimonides Medical Center — Brooklyn, New York
  • Roswell Park Cancer Institute — Buffalo, New York
  • Memorial Sloan Kettering Commack — Commack, New York
  • Memorial Sloan Kettering Westchester — Harrison, New York
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tu…

Sponsor: Xencor, Inc.
NCT ID: NCT06276491
Sites in New York:
  • Icahn School of Medicine at Mount Sinai — New York, New York
  • Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ov…

Sponsor: Context Therapeutics Inc.
NCT ID: NCT06515613
Sites in New York:
  • Memorial Sloan Kettering Cancer Center — New York, New York
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Brodalumab in the Treatment of Immune-Related Adverse Events

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who p…

Sponsor: Brian Henick, MD
NCT ID: NCT06673329
Sites in New York:
  • Columbia University Irving Medical Center — New York, New York
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in New York:
  • Montefiore Medical Center-Einstein Campus — The Bronx, New York
  • Montefiore Medical Center-Weiler Hospital — The Bronx, New York
  • Children's Hospital at Montefiore — The Bronx, New York
  • Montefiore Medical Center - Moses Campus — The Bronx, New York
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in New York:
  • Massive Bio SYNERGY-AI site — Buffalo, New York
  • Massive Bio SYNERGY-AI site — Hempstead, New York
  • Massive Bio SYNERGY-AI site — Manhasset, New York
  • Massive Bio SYNERGY-AI site — New York, New York
  • Massive Bio SYNERGY-AI site — Staten Island, New York
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in New York:
  • C.R. Wood Cancer Center, Glens Falls Hospital — Glens Falls, New York
  • Faxton St. Luke's Healthcare, Mohawk Valley — Utica, New York
View on ClinicalTrials.gov →
Recruiting Academic/Other

Germ Cell Tumor and Testicular Tumor DNA Registry

This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT02099734
Sites in New York:
  • Cold Springs Harbor Laboratory (Specimen Analysis) — Cold Spring Harbor, New York
  • Memorial Sloan Kettering Commack — Commack, New York
  • Memorial Sloan Kettering Westchester — Harrison, New York
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • Memorial Sloan Kettering Nassau — Uniondale, New York
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20